Spinocerebellar Ataxias

Neurology
2
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 1 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Biohaven
BiohavenNEW HAVEN, CT
3 programs
1
1
troriluzolePhase 3Small Molecule1 trial
TroriluzolePhase 2/3Small Molecule1 trial
BHV-4157N/A1 trial
Active Trials
NCT06529146Active Not RecruitingEst. Jun 2026
NCT02960893CompletedEst. Sep 2024
NCT03701399Active Not RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biohaventroriluzole
BiohavenTroriluzole
BiohavenBHV-4157

Clinical Trials (3)

Troriluzole in Adult Participants With Spinocerebellar Ataxia

Start: Mar 2019Est. completion: Jun 2026
Phase 3Active Not Recruiting

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

Start: Dec 2016Est. completion: Sep 2024
Phase 2/3Completed

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Start: Mar 2019Est. completion: Jun 2026
N/AActive Not Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
1 companies competing in this space